Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes. This project is translational and has the potential to lead to future translational research opportunities, including interventional trials in which therapeutic escalation is offered at the early circulating tumor DNA (ctDNA) molecular residual disease (MRD) detection timepoint. Ultimately, the integration of ctDNA into the clinical workflow has the potential to enhance cancer diagnosis, treatment, surveillance, and prognosis, and guide clinical decision-making in this era of personalized precision medicine.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• Eligible healthy donors will be at least 18 years of age.
Locations
United States
Missouri
Washington University School of Medicine
RECRUITING
St Louis
Contact Information
Primary
Melissa Reimers, M.D.
cbumb@wustl.edu
314-362-7249
Time Frame
Start Date: 2019-05-29
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 100
Treatments
Healthy Donor Samples
* Donation of blood and/or urine samples as often as bi-monthly and as many as 24 times in total~* These samples will be used to generate reference data to compare patient data to and/or to correct stereotypic noise.
Samples from Repository and Banking Studies
* Healthy prostate and/or blood and/or urine samples from Genitourinary Repository~* Tissue, blood, and/or drain fluid samples from Head and Neck Banking studies~* Tissue and/or blood samples from Esophageal Repository~* Tissue and/or blood samples from Genitourinary Repository~* Tissue and/or plasma from Sarcoma Tissue Bank~* Tissue and/or plasma from Breast Cancer Bank~* Tissue, plasma, and/or urine from GI Tissue and Blood Bank~* Tissue, blood, and/or urine from Solid Tumor Bank~* Tissue, blood, and/or urine from Lung Cancer Bank~* Tissue and/or blood from Skin Cancer Bank~* Tissue and/or blood from Pediatric Neurosurgery Tissue Bank
Authors
Related Therapeutic Areas
Sponsors
Leads: Washington University School of Medicine
Collaborators: The Foundation for Barnes-Jewish Hospital, The V Foundation for Cancer Research, Skandalaris, National Center for Advancing Translational Sciences (NCATS), Radiological Society of North America, National Institute of General Medical Sciences (NIGMS), Roche Sequencing Solutions